Pharvaris N.V.

XNAS

Last traded price · USD

$34.46

+0.38%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 17:48 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $34.33
Volume: 1
Day's high: —
Day's low: —

In brief

Pharvaris N.V. is a US-listed company listed on Nasdaq, valued at about $2.42B.
Its shares closed at $34.33 on 4 Nov 2026, up 58.6% over the past year.
From India you can buy PHVS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Pharvaris N.V. (PHVS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PHVS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PHVS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +10.3% (SPY −1.6%). 3 months: +2.7% (SPY −0.4%). 1 year: +58.6% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PHVS, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $34.33 was 2.5% above its 50-day average ($33.50) and 10.3% above its 200-day average ($31.12). It has closed above the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed above the 200-day on 23 Jul 2025, 324 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 311.4K shares was 0.5× the average of the 30 sessions before it (675.8K), as the price fell 1.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
60% of the way up its 52-week range
Closed at $34.33 on 4 Nov 2026: 20.6% below the 52-week high of $43.25 (8 Sep 2026) and 63.3% above the low of $21.02 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 3.8% of shares outstanding
2.5M shares were sold short at the 15 Oct 2026 settlement, 3.8% of the 65.4M shares outstanding; covering them would take 4.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+10.3%

6 months+14.0%

1 year+58.6%

5 years+126.6%

Newswire

About

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Website

Notable moves

June 26, 2023
+27.76%
December 8, 2022
+356.57%
August 22, 2022
−34.32%

Newswire

About

Website

Notable moves

June 26, 2023
+27.76%
December 8, 2022
+356.57%
August 22, 2022
−34.32%

Pharvaris N.V.

XNAS

Last traded price · USD

$34.46

+0.38%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 17:48 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $34.33
Volume: 1
Day's high: —
Day's low: —

In brief

Pharvaris N.V. is a US-listed company listed on Nasdaq, valued at about $2.42B.
Its shares closed at $34.33 on 4 Nov 2026, up 58.6% over the past year.
From India you can buy PHVS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Pharvaris N.V. (PHVS) shares from India?

Do I need the price of a whole PHVS share to invest?

How much can I invest in US stocks in a year?

Can I trade PHVS options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY over 1 year
1 month: +10.3% (SPY −1.6%). 3 months: +2.7% (SPY −0.4%). 1 year: +58.6% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PHVS, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $34.33 was 2.5% above its 50-day average ($33.50) and 10.3% above its 200-day average ($31.12). It has closed above the 200-day for 9 sessions, since 23 Oct 2026. The 50-day average crossed above the 200-day on 23 Jul 2025, 324 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Light volume: 0.5× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 311.4K shares was 0.5× the average of the 30 sessions before it (675.8K), as the price fell 1.3%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
60% of the way up its 52-week range
Closed at $34.33 on 4 Nov 2026: 20.6% below the 52-week high of $43.25 (8 Sep 2026) and 63.3% above the low of $21.02 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 3.8% of shares outstanding
2.5M shares were sold short at the 15 Oct 2026 settlement, 3.8% of the 65.4M shares outstanding; covering them would take 4.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+10.3%

6 months+14.0%

1 year+58.6%

5 years+126.6%

Newswire

About

Website

Notable moves

June 26, 2023
+27.76%
December 8, 2022
+356.57%
August 22, 2022
−34.32%

Newswire

About

Website

Notable moves

June 26, 2023
+27.76%
December 8, 2022
+356.57%
August 22, 2022
−34.32%

Pharvaris N.V.

Pharvaris N.V. in brief

Ahead of SPY over 1 year

Above its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

60% of the way up its 52-week range

Short interest at 3.8% of shares outstanding

Pharvaris N.V.

Pharvaris N.V. in brief

Ahead of SPY over 1 year

Above its 50- and 200-day averages

Light volume: 0.5× its 30-session average on 4 Nov 2026

60% of the way up its 52-week range

Short interest at 3.8% of shares outstanding